Skip to main content
[Preprint]. 2023 Jul 13:2023.07.12.548696. [Version 1] doi: 10.1101/2023.07.12.548696

Figure 5. Low dose (50mg/kg/bw) ABT-263 treatment of Apoe−/− mice with advanced lesions was associated with increased hepatic fibrosis.

Figure 5.

(A) Experimental design, EC-lineage tracing Apoe−/− mice were fed a WD for 18 weeks followed by 50mg/kg/bw ABT-263 treatment on WD for 9 weeks. (B) Percentage of mice showing an abnormal liver phenotype. (C) Representative photographs of mice showing an abnormal live phenotype with ABT-263 treatment. (D) Masson trichrome stain to detect the fibrous tissue (blue) in the liver sections from the vehicle and ABT-263 treated mice. (E) Percentage mice showing fibrous tissue (blue) in the liver sections from the vehicle and ABT-263 treated mice. (F) ALT and (G) AST levels measured in plasma. Mann-Whitney U-tests were used for statistical analysis in F and G, and biologically independent animals are indicated as individual dots. Error bars show the SEM. The p-values are indicated on the respective graphs.